Figure 2 - uploaded by Kimihiro Shimizu
Content may be subject to copyright.
Chemical structure of thymine labeled with fluorescent dyes. A : Thiazole pink-labeled thymine. B : Thiazole orange-labeled thymine. doi:10.1371/journal.pone.0060151.g002 

Chemical structure of thymine labeled with fluorescent dyes. A : Thiazole pink-labeled thymine. B : Thiazole orange-labeled thymine. doi:10.1371/journal.pone.0060151.g002 

Source publication
Article
Full-text available
Genetic polymorphisms in the human MDM2 gene are suggested to be a tumor susceptibility marker and a prognostic factor for cancer. It has been reported that a single nucleotide polymorphism (SNP) c.309T>G in the MDM2 gene attenuates the tumor suppressor activity of p53 and accelerates tumor formation in humans. In this study, to detect the SNP c.30...

Context in source publication

Context 1
... primer set and an enzyme, Aac polymerase [18], which has strand displacing activity and a high resistance to cellular contaminants. More recently, we have developed exciton-controlled hybridization-sensitive fluorescent primers, named ‘‘Exciton Primers’’ or ‘‘Eprimers,’’ which function as sequence-specific dyes that significantly enhance the signal/noise ratio [26–28]. After hybridization to complementary sequences, the Eprimer provides a sequence-specific fluorescent signal for real-time monitoring of amplification reactions. Eprimers show high signal strength with low background leading to a superior specificity and sensitivity compared with the commonly used SYBR H Green I [28]. To further advance our technology, in the present study, we introduced novel primers as well as two Eprimers to detect both 309T and 309G alleles simultaneously in one tube. We examined the specificity and reliability of the new method by comparison with the conventional PCR-based method. We here present validation data obtained with the new method named ‘‘Duplex SmartAmp’’ and demonstrate its genotyping data with clinical samples of lung cancer patients. Figure 1A depicts a schematic illustration of the strategy for detecting SNP (c.309G . T) in the MDM2 gene by the Duplex SmartAmp method. To achieve high fidelity of SNP typing, we introduced two novel primers, namely, the outer Boost Primer (oBP) and the neutral Boost Primer (nBP), in addition to the standard SmartAmp primers ( i.e ., TP, FP, BP, and OP). The reason for adopting such a SNP typing strategy is that GC- rich nucleotide sequences were found in both 5 9 - and 3 9 -regions adjacent to the SNP (c.309T . G), as shown in Figure 1B. In other words, the melting temperature of the GC-rich regions was so high that dissociation of the DNA strands became slower during the isothermal DNA amplification reaction. Two oBPs, i.e ., oBP (WT) and oBP (SNP), were designed to discriminate T and G, respectively, at nucleotide c.309 between the wild type (WT) and SNP alleles (Figure 1B). These two oBPs were labeled with differently colored fluorescence dyes, as described below. The nBP served as a pacemaker for the detection reaction, where it is annealed at a locus proximal to the SNP position (Figure 1B). The Duplex SmartAmp method requires the use of seven different primers: TP, FP, BP, OP, nBP, oBP (WT), and oBP (SNP). These primer candidates were selected on the basis of algorithms for free energy, probability of base-pairing, and product size range [29]. After extensive screening with a variety of synthesized oligo-nucleotides as primer candidates, we have selected one optimal set to use in the Duplex SmartAmp method for detecting SNP 309T . G in the MDM2 gene. Table 1 summarizes the sequences of those primers comprising the optimal set. The genomic sequence located between the annealing sites of TP and FP (Figure 1A) is the target region that is amplified by the isothermal DNA amplification reaction. oBP (WT) and oBP (SNP) were separately labeled with fluorescence dyes named thiazole pink and thiazole orange, respectively. One thymine in each of those oBPs was chemically linked with either thiazole pink or thiazole orange molecules at the position ‘‘Z’’ or ‘‘U’’ in the primer sequence (Table 1). Thyamine bases, except for both 3 9 - and 5 9 -terminals, can be labeled with exciton dyes. The sequence of Eprimers should be computation- ally designed to avoid any possibility of inter-primer dimmer formation and self-folding within a primer. Figure 2 represents the chemical structures of the thiazole pink (A) and thiazole orange (B) molecules. To detect the fluorescence of those dyes intercalated into DNA double strands during the Duplex SmartAmp reaction, thiazole pink and thiazole orange were excited at 585 and 492 nm, respectively, and their fluorescence was detected through the respective ROX (610 nm) and FAM (516 nm) filters in a real-time PCR machine Mx3000P (Agilent Technologies, Santa Clara, CA, USA). These primers selectively recognized the target sequence of SNP c.309T . G of the MDM2 gene to discriminate homozygous 309T/T, heterozygous 309T/G, and homozygous 309G/G. As shown in Figure 3, the fluorescence intensity reached a plateau in 30 minutes over time for both the genomic DNA (upper panels) and blood (lower panels) samples. To verify amplification products, by agarose gel electrophoresis, we analyzed the DNA amplicons formed during the reaction of Duplex SmartAmp assay. We sampled aliquots of ...

Citations

... Called "Exciton probe-Eprobe" [18,19] or "Exciton primer-Eprimer", ECHOs are oligonucleotides that only emit fluorescence upon binding to their sequence specific targets. So far, SmartAmp has been used for SNP genotyping (wild-type vs mutant) either with one [20] or duplex Eprimer labelling [21][22][23]. ...
Article
Full-text available
Background SmartAmp-Eprimer Binary code (SEB) Genotyping is a novel isothermal amplification method for rapid genotyping of any variable target of interest. Methods After in silico alignment of a large number of sequences and computational analysis to determine the smallest number of regions to be targeted by SEB Genotyping, SmartAmp primer sets were designed to obtain a binary code of On/Off fluorescence signals, each code corresponding to a unique genotype. Results Applied to HBV, we selected 4 targets for which fluorescence amplification signals produce a specific binary code unique to each of the 8 main genotypes (A–H) found in patients worldwide. Conclusions We present here the proof of concept of a new genotyping method specifically designed for complex and highly variable targets. Applied here to HBV, SEB Genotyping can be adapted to any other pathogen or disease carrying multiple known mutations. Using simple preparation steps, SEB Genotyping provides accurate results quickly and will enable physicians to choose the best adapted treatment for each of their patients.
... Some had already reported its utility for detecting a single nucleotide polymorphism (SNP). Besides, the method has prevailed in several fields of medicine [6][7][8]. SmartAmpSARS-CoV-2 kit (DANA-FORM Inc., Tokyo, Japan) was commercialized to diagnose COVID-19 in July 2021 in Japan. We evaluated the efficacy and validity of the SmartAmp assay for the diagnosis of COVID-19. ...
... Although the gold standard diagnostic testing for COVID-19 is rRT-PCR, SmartAmp assay has several advantages in managing the COVID-19 patients. This method can reduce medical costs, showing a lower cost of 1980 Japanese yen (JPY), which is about 18 USD per sample [7], while PCR is more costly, showing about 250-300 USD per sample in Japan [5]. It takes 25-45 min after preprocessing to diagnose the disease, which is much shorter than rRT-PCR. ...
Article
Full-text available
Introduction: The pandemic of a novel coronavirus disease 2019 (COVID-19) caused by a severe acute respiratory coronavirus 2 (SARS-CoV-2) infection has been problematic worldwide. A new SARS-CoV-2 diagnostic test (SmartAmp) was licensed in Japan in July 2021. This method, which enables us to diagnose COVID-19 as well as a gene mutation on the virus, is promising to reduce medical costs and staff labor. Patients and methods: To analyze the diagnostic accuracy of the SmartAmp assay for diagnosing COVID-19, we performed this retrospective study at our institute during April and May 2021. We compared the results of the SmartAmp assay and real-time reverse transcription-polymerase chain reaction (rRT-PCR) using a saliva sample from individuals suspected as having COVID-19. Results: Out of 70 samples tested, the SmartAmp assay had 50 (71%) positive and 20 (29%) negative results. Using rRT-PCR as a reference, the diagnostic accuracy displayed a sensitivity of 84%, a specificity of 95%, a positive predictive value of 97.7%, and a negative predictive value of 70.4%. On the other hand, false-negative cases were found in 7 (10%), and there was no significant difference of Ct-value between true positive and false negative cases (Mean Ct-value 25.2 vs. 27.5 cycles, p = 0.226 by Mann-Whitney U test). Conclusion: The SmartAmp assay is a valuable method to diagnose COVID-19 rapidly. However, the negative predictive value is not high enough to diagnose the disease, so that negative results should be considered for rRT-PCR testing if patients are suspected of having COVID-19.
... To detect this SNP, the authors have developed a new SNP detection method with two different colored exciton dye-labeled primers (Eprimers) for each variant (309T and 309G, respectively). The method, named Duplex SmartAmp, enables us to simultaneously detect both alleles in one tube and to detect them directly in a small amount of genomic DNA or blood sample [29]. The authors, then, confirmed effectiveness of Duplex SmartAmp by comparing the results derived from 96 genomic DNA and 24 blood samples to those obtained by using the conventional PCR-restriction fragment length polymorphism (RFLP) method; the results of both methods were in a full agreement. ...
Chapter
Full-text available
Rapid advances of genomic technologies in medical sciences resulted in growth of identified molecular biomarkers, including those required for proper drug administration and therapy selection in pulmonary diseases. While high-throughput technologies are powerful tool for wide screening, targeted real-time monitoring using nucleic acid amplification is still the most important method for DNA and RNA detection widely employed in clinical diagnostics. In this chapter, we overview the key nucleic acid amplification platforms successfully used in the clinical diagnostics, including that associated with pulmonary diseases, and briefly outline their advantages and pitfalls. We further focus on the specific isothermal amplification technology SmartAmp and Eprobes developed by RIKEN outlining its implementation in quick and robust detection of several clinically important SNP and cancer-associated somatic mutations. Finally, we describe the further potential of expansion of utilization of Eprobes platform for direct protein detection for clinical diagnostic needs.
... The DNA was used for SNP typing of c.309T>G and p53 Arg72Pro polymorphisms. Genotyping of c.309T>G was carried out using the Duplex SmartAmp method as described previously [22]. p53 Arg72Pro was genotyped using polymerase chain reactionrestriction fragment length polymorphism (PCR-RFLP) based on a previous report [23]. ...
... Although our findings need to be validated in prospective studies, c.309T>G would be a useful prognostic marker that is detectable at any stage of diagnosis or treatment and influences the therapeutic strategies. Furthermore, we had already established the Duplex SmartAmp method [22] to detect c.309T>G with a single drop (5 μL) of blood within 40 min from sample collection. If we can make this method more practical, we will detect this SNP more easily and quickly in any clinical situation. ...
... The genotype frequencies of MDM2 polymorphisms were as follows: T/T, 20.8%; T/G, 48.6%; andG/G, 30.7%. The frequency of the MDM2 309G allele was 0.55, consistent with previously described values for Asian lung AC patients[22]. ...
Article
Full-text available
The MDM2 protein plays an important role in the regulation of cell proliferation and apoptosis via ubiquitination and proteasome-mediated degradation of p53. The genetic polymorphism rs2279744 (c.309T>G) of the MDM2 gene is reportedly associated with susceptibility and/or prognosis in various cancers. In this study, we investigated the risk factors for worse survival in patients with lung adenocarcinoma (AC). We examined the association between c.309T>G and the prognosis of lung cancer by retrospectively reviewing 453 lung cancer patients. We studied both, clinicopathological and genetic characteristics, including the c.309T>G, p53 Arg72Pro, EGFR, KRAS, and p53 mutations. Associations between these factors and survival outcome were analyzed using Cox proportional hazards models. The frequencies of MDM2 polymorphisms were T/T, 20.8%; T/G, 48.6%, and G/G, 30.7%. The overall survival (OS) of AC patients with pathological stage I disease and the MDM2 T/T genotype was significantly shorter than that of those with the T/G or G/G genotypes (P = 0.02). Multivariate analysis revealed that the MDM2 T/T genotype was an independent, significant prognostic factor (hazard ratio [HR] = 2.23; 95% confidence interval [CI]: 1.07-4.65; P = 0.03). The MDM2 T/T genotype was predictive of poorer survival in a Japanese population. Genotyping for this polymorphism might predict the clinical outcomes of stage I AC patients.
... 3 With its accuracy, sequencing is always regarded as a golden standard for nucleic acid analysis, but as per the scale of investigation and the subsequent massive data analysis, sequencing is more suitable for discovery of novel SNPs 4-6 than direct detection of specifically known SNPs. Other technologies including DNA microarrays, 7-9 real-time polymerase chain reaction (RT-PCR), 10,11 high resolution melting (HRM), 12 MassARRAY, 13,14 the multiplex PCR-RFLP method 15 and isothermal DNA amplification 16,17 also offer sensitive tools to detect SNPs. However, these techniques require tedious experimental procedures and expensive and sophisticated instruments that may not be available in many laboratories. ...
Article
Full-text available
Current techniques for single nucleotide polymorphisms (SNP) detection require tedious experimental procedures and expensive and sophisticated instruments. In this study, a visual genotyping method has been successfully established via combining ARMS-PCR with gold magnetic nanoparticles (GoldMag)-based lateral flow assay (LFA) and applied to the genotyping of methylenetetrahydrofolate reductase (MTHFR) C677T. C677T substitution of the gene MTHFR leads to an increased risk of diseases. The genotyping result is easily achievable by visual observation within 5 minutes after loading of the PCR products onto the LFA device. The system is able to accurately assess a broad detection range of initial starting genomic DNA amount from 5 ng to 1200 ng per test sample. The limit of detection reaches 5 ng. Furthermore, our PCR-LFA system was applied to clinical trials for screening 1,721 individuals on the C677T genotypes. The concordance rate of the genotyping result detected by PCR-LFA was up to 99.6% when compared with the sequencing results. Collectively, our PCR-LFA has been proven rapid, accurate, sensitive, and inexpensive. This new method is highly applicable for C677T SNP screening in the laboratories and clinical practices. More promisingly, it could also be extended to the detection of SNPs of other genes.
... product development. A variety of different SNP detection methods have lately been described [169][170][171]. Kawai et al. report about a first Influenza A (H1N1) assay, combining both a reverse transcriptase and a SmartAmp amplification in one-step setup. ...
Article
Full-text available
Nucleic acid amplification technologies (NAATs) offer the most sensitive tests in the clinical laboratory. These techniques are used as a powerful tool for screening and diagnosis of infectious diseases. Isothermal methods, as an alternative to polymerase chain reaction (PCR), require no thermocycling machine and can mostly be performed with reduced time, high throughput, and accurate and reliable results. However, current molecular diagnostic approaches generally need manual analysis by qualified and experienced personal which is a highly complex, time-consuming and labor-intensive task. Thus, the demand for simpler, miniaturized systems and assays for pathogen detection is steadily increasing. Microfluidic platforms and lab-on-a-chip devices have many advantages such as small sample volume, portability and rapid detection time and enable point-of-care diagnosis. In this article, we review several isothermal amplification methods and their implementation in microsystems in relation to quantification of nucleic acids.
... The aim of the present study was to investigate whether a functionally important SNP, MDM2 SNP309, was associated with the risk of lung cancer in a Japanese population. The genomic DNA was examined from blood samples for c.309T>G using the Smart Amplification Process (SmartAmp), which is a rapid, sensitive and simple mutation-detection assay that has been described previously (35,36). Subsequently, the association between c.309T>G and the lung cancer risk was examined. ...
... Peripheral venous blood samples were collected and DNA was extracted using a DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Genotyping of c.309T>G in the MDM2 gene was performed by the Duplex SmartAmp method as described previously (36) with an Mx3000P PCR system (Agilent Technologies, Santa Clara, CA, USA). The lung cancer tissues were immediately frozen following surgical removal and stored at -80˚C until DNA extraction using a Wizard Genomic DNA purification kit (Promega Corporation, Madison, WI, USA). ...
Article
Full-text available
Molecular-targeted therapy has not been established in non-adenocarcinoma lung cancer (non-AdLC), as no targets that affect the clinical efficacy of molecular-targeted drugs have yet been identified. In this study, we investigated the frequency of genetic variations in discoidin domain receptor 2 (DDR2), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), epidermal growth factor receptor (EGFR) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) in non-AdLC patients, in order to evaluate the possibility of genetic mutations in these genes being used as therapeutic targets for the treatment of patients with non-AdLC. For this purpose, we enrolled 150 non-AdLC patients who had undergone surgery at the Gunma University Hospital between December, 2003 and December, 2012. Genetic mutations in the EGFR, KRAS, DDR2 and BRAF genes were detected by a sequencing method or probe assay using DNA derived from cancer tissues. No somatic mutations in DDR2 or BRAF were detected in non-AdLC patients. Conversely, genetic mutations in EGFR exon 19 were found in 3 squamous cell carcinoma (SCC) and 3 adenosquamous carcinoma patients, whereas KRAS codon 12 mutations were also found in 3 SCC patients and 1 large-cell neuroendocrine carcinoma patient. EGFR and KRAS mutations were mutually exclusive. This study indicated that, although DDR2 and BRAF mutations may only rarely be used as therapeutic targets, EGFR and KRAS mutations may represent candidate therapeutic targets, at least in the non-AdLC patients investigated.
... The aim of the present study was to investigate whether a functionally important SNP, MDM2 SNP309, was associated with the risk of lung cancer in a Japanese population. The genomic DNA was examined from blood samples for c.309T>G using the Smart Amplification Process (SmartAmp), which is a rapid, sensitive and simple mutation-detection assay that has been described previously (35,36). Subsequently, the association between c.309T>G and the lung cancer risk was examined. ...
... Peripheral venous blood samples were collected and DNA was extracted using a DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Genotyping of c.309T>G in the MDM2 gene was performed by the Duplex SmartAmp method as described previously (36) with an Mx3000P PCR system (Agilent Technologies, Santa Clara, CA, USA). The lung cancer tissues were immediately frozen following surgical removal and stored at -80˚C until DNA extraction using a Wizard Genomic DNA purification kit (Promega Corporation, Madison, WI, USA). ...
Article
Full-text available
Murine double minute 2 (MDM2) is a negative regulator of p53. A single-nucleotide polymorphism (SNP) (rs2279744: c.309T>G) in the promoter region of the MDM2 gene has been shown to result in higher levels of MDM2 RNA and protein. Regarding the contribution of c.309T>G in the MDM2 gene to the lung cancer risk, previous studies are conflicting. In order to evaluate the association between c.309T>G and the lung cancer risk, a case-control study was performed. The MDM2 genotypes were determined in 762 lung cancer patients and in 700 cancer-free control subjects using the Smart Amplification Process. Statistical adjustment was performed for gender, age and pack-years of smoking. The distributions of c.309T>G (T/T, T/G, G/G) were 20.1, 49.7, 30.2% in the case group and 21.7, 47.9, 30.4% in the healthy-control group. There were no overall associations between the MDM2 genotypes and the risk of lung cancer [T/G genotype: Adjusted odds ratio (AOR), 1.30; 95% confidence interval (CI), 0.88-1.93; and G/G genotype: AOR, 1.18; 95% CI, 0.78-1.80]. The subgroup analysis of gender, histology, smoking status and epidermal growth factor receptor mutation status also indicated that there was no association with lung cancer. Additionally, the genotypes did not have an effect on the age at the time of diagnosis of lung cancer (P=0.25). In conclusion, the G allele frequency in the lung cancer cases was 0.551, which was similar to other studies. The results of the present study suggest that the c.309T>G is not significantly associated with lung cancer.
... The DNA was used for SNP typing of c.309T>G and p53 Arg72Pro polymorphisms. Genotyping of c.309T>G was carried out using the Duplex SmartAmp method as described previously [22]. p53 Arg72Pro was genotyped using polymerase chain reactionrestriction fragment length polymorphism (PCR-RFLP) based on a previous report [23]. ...
... Although our findings need to be validated in prospective studies, c.309T>G would be a useful prognostic marker that is detectable at any stage of diagnosis or treatment and influences the therapeutic strategies. Furthermore, we had already established the Duplex SmartAmp method [22] to detect c.309T>G with a single drop (5 μL) of blood within 40 min from sample collection. If we can make this method more practical, we will detect this SNP more easily and quickly in any clinical situation. ...
... The genotype frequencies of MDM2 polymorphisms were as follows: T/T, 20.8%; T/G, 48.6%; andG/G, 30.7%. The frequency of the MDM2 309G allele was 0.55, consistent with previously described values for Asian lung AC patients[22]. ...
... This, in turn, attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans [45]. Asians, including Japanese, have higher frequencies of the 309G allele as compared with African-Americans and Caucasians [46]. It has been reported that this polymorphism in the MDM2 gene is associated with the prognosis for several types of tumors, including lung cancer [47]. ...
... After genomic DNA was denatured at 98uC for 3 min, the genotyping reactions were allowed to proceed isothermally at 60uC for 60 min in a Mx3000P PCR system (Agilent Technologies, Santa Clara, CA, USA). The SNP c.309T.G in of the MDM2 gene were detected by the Duplex SmartAmp method, as described previously [46]. ...
Article
Full-text available
The transcription factor NRF2 plays a pivotal role in protecting normal cells from external toxic challenges and oxidative stress, whereas it can also endow cancer cells resistance to anticancer drugs. At present little information is available about the genetic polymorphisms of the NRF2 gene and their clinical relevance. We aimed to investigate the single nucleotide polymorphisms in the NRF2 gene as a prognostic biomarker in lung cancer. We prepared genomic DNA samples from 387 Japanese patients with primary lung cancer and detected SNP (c.-617C>A; rs6721961) in the ARE-like loci of the human NRF2 gene by the rapid genetic testing method we developed in this study. We then analyzed the association between the SNP in the NRF2 gene and patients' overall survival. Patients harboring wild-type (WT) homozygous (c.-617C/C), SNP heterozygous (c.-617C/A), and SNP homozygous (c.-617A/A) alleles numbered 216 (55.8%), 147 (38.0%), and 24 (6.2%), respectively. Multivariate logistic regression models revealed that SNP homozygote (c.-617A/A) was significantly related to gender. Its frequency was four-fold higher in female patients than in males (10.8% female vs 2.7% male) and was associated with female non-smokers with adenocarcinoma. Interestingly, lung cancer patients carrying NRF2 SNP homozygous alleles (c.-617A/A) and the 309T (WT) allele in the MDM2 gene exhibited remarkable survival over 1,700 days after surgical operation (log-rank p = 0.021). SNP homozygous (c.-617A/A) alleles in the NRF2 gene are associated with female non-smokers with adenocarcinoma and regarded as a prognostic biomarker for assessing overall survival of patients with lung adenocarcinoma.